文献速递骨软组织肉瘤与黑色素瘤

侵袭性血管黏液瘤的自然病程与治疗结局:单中心经验

Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience.
PubMed 文献 · Eur J Cancer · 2026-09-02

初始治疗以手术为主(30例),系统治疗8例,观察2例。手术患者10年OS估计为95%,R0/R1切除者中位RFS 49.8个月,内分泌治疗ORR 25%。结论认为AA长期生存良好,内分泌治疗有客观活性,部分稳定患者可观察或延迟干预。

要点

  • AA手术切除后长期生存极好,但局部复发常见,需个体化随访。
  • 内分泌治疗在部分患者中显示客观疗效,ORR 25%,中位DOT 15.4个月。
  • 对临床稳定的未治疗或残留病灶患者,观察或延迟干预可行。

核心结论

  • AA患者尽管术后复发或需后续干预频繁,但长期生存极好。
  • 内分泌治疗在部分患者中显示客观活性。
  • 对选定的临床稳定、未治疗或残留宏观病灶患者,观察或延迟干预可行。

研究设计与样本

  • 中位年龄42岁,87.5%为女性,中位肿瘤大小9.9 cm。
  • 初始治疗:手术30例,系统治疗8例,观察2例。

主要发现

  • 初始手术患者中位随访68.6个月,中位OS未达到,估计10年OS为95%(95% CI,68%-99%)。
  • R0/R1切除患者中位RFS为49.8个月(95% CI,21.0-64.7),3年RFS为56%(95% CI,31%-75%)。
  • 肿瘤大小和切缘状态与复发无显著关联。
  • 2例初始观察及3例R2切除后残留宏观病灶患者长期无需进一步干预。

关键数值与推荐

  • 手术患者估计10年OS为95%(95% CI,68%-99%)。
  • R0/R1切除患者中位RFS为49.8个月(95% CI,21.0-64.7),3年RFS为56%(95% CI,31%-75%)。
  • 系统治疗(以内分泌为主)ORR为25%,中位DOT为15.4个月。

临床怎么用

  • 手术仍是主要初始治疗,但需关注功能保留与个体化选择。
  • 内分泌治疗可作为系统治疗选项,尤其对不可切除或复发患者。
  • 对临床稳定的未治疗或残留病灶患者,可考虑观察或延迟干预。
  • 放疗极少使用,不作为常规推荐。

局限性

  • 观察和延迟干预的适用人群需前瞻性研究明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aggressive angiomyxoma (AA) is a rare, locally infiltrative mesenchymal tumor with frequent local recurrence. Optimal management remains poorly defined, particularly the roles of surgery, endocrine therapy, and observation. METHODS: We retrospectively analyzed patients with histologically confirmed AA treated at a single institution from 2000 to 2024. Clinical, pathologic, and treatment data were collected. Overall survival (OS), relapse-free survival (RFS), duration of treatment (DOT), and radiographic response by quasi-RECIST 1.1 were assessed descriptively. RESULTS: Forty patients were included; median age was 42 years, 87.5% were female, and median tumor size was 9.9 cm. Initial management was surgery in 30 patients, systemic therapy in 8, and observation in 2. Among patients initially managed with surgery, median OS from the time of first resection was not reached at a median follow-up of 68.6 months; estimated 10-year OS was 95% (95% CI, 68%-99%). Among patients with R0/R1 resection, median RFS was 49.8 months (95% CI, 21.0-64.7), with 3-year RFS of 56% (95% CI, 31%-75%). Tumor size and margin status were not significantly associated with recurrence. Thirteen patients received systemic therapy, predominantly endocrine-based; ORR was 25% and median DOT was 15.4 months. Two patients were initially observed, and three with residual macroscopic disease after R2 resection remained free from further intervention for prolonged periods. Radiation therapy was rarely used. CONCLUSIONS: AA was associated with excellent long-term survival despite frequent recurrence or subsequent intervention after surgery. Endocrine therapy showed objective activity in a subset of patients. Observation or delayed intervention may be feasible in selected, clinically stable patients with untreated or residual macroscopic disease, supporting individualized, function-preserving management focused on symptoms, morbidity, and patient preferences.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Babatunde OO, Seier K, Desir-Camille R, et al. Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience. Eur J Cancer. 2026. PMID: 42696841. doi:10.1016/j.ejca.2026.117012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。